EWG CRITERIA

- developing country impact
- financial aspects
- operational efficiencies

FINANCING MECHANISMS

- A new indirect tax (a consumer based tax)
- Voluntary business and consumer contributions
- Taxation of repatriated pharmaceutical profits
- New donor funds for health R&D

FINAL SELECTED PROPOSALS

Four financing mechanisms that will triple available funds for R&D for neglected diseases of the developing world

Five funding allocation mechanisms that the EWG believes will optimally allocate both existing funds and new funds raised by the four proposed financing mechanisms

Two efficiency proposals aimed at cutting R&D costs across the board

FUNDING ALLOCATION MECHANISMS

- Funding via Product Development Partnerships (PDPs)
- Direct grants to small companies and grants for DC trials
- Milestone Prizes: Innocentive
- End-Prizes (cash): Rapid Diagnostic Test for TB
- Purchase or procurement agreements

EFFICIENCY PROPOSALS

- Regulatory harmonization (Dev Country-focused)
- Pre-competitive R&D platforms